Form 4: Semler Scientific CEO Douglas Murphy-Chutorian Granted Stock Options

Sentiment:

SEC Form 4 Filing


Semler Scientific's CEO, Douglas Murphy-Chutorian, was granted stock options for 15,000 shares on May 10, 2024, according to a Form 4 filing.

Summary

  • Douglas Murphy-Chutorian, CEO of Semler Scientific, Inc., was granted stock options to purchase 15,000 shares of common stock on May 10, 2024.
  • The exercise price of the options is $22.92 per share.
  • The options vest over four years, with 1/4th vesting on the first anniversary of the grant date and the remaining 3/4ths vesting monthly thereafter.
  • The options expire on May 10, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no negative aspects presented in the document.

Positives

  • The granting of stock options to the CEO aligns his interests with those of the shareholders.
  • The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Stock option grants are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

  • Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like Semler Scientific's.
  • Vesting schedules, such as the four-year vesting period described, are standard practice to incentivize long-term performance.
  • Comparing the size of the grant (15,000 shares) to similar companies would require analyzing their executive compensation policies and outstanding share counts.

Stakeholder Impact

  • The stock option grant could positively impact shareholders by incentivizing the CEO to increase the company's value.
  • The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

DateDescription
2023-07-31Date of Power of Attorney execution.
2024-05-10Date of stock option grant and transaction.
2024-05-14Date of signature for the Form 4 filing.
2034-05-10Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.